#ES­MO18: Car­dio dreams blight­ed, No­var­tis show­cas­es its “block­buster” am­bi­tions for ra­dio­phar­ma­ceu­ti­cals

No­var­tis down­played the painful news yes­ter­day that the FDA had spurned its ap­pli­ca­tion for canakinum­ab as a car­dio drug, im­per­il­ing its lat­est block­buster am­bi­tions …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER